Table 3.
Solute clearances favoring furosemide clearance compared with iGFR (above 90th percentile regression line)
| −log(P): Furosemide | −log(P): iGFR | Compound | Protein Binding (%) | CoV | CLr-to-CrCl Ratio |
|---|---|---|---|---|---|
| 7.9 | 4.6 | L-Homocitrulline | 11 | 0.3 | 3.0 |
| 7.5 | 5.6 | 2-[(4-Aminobenzoyl)amino]acetic acid | 19 | 0.3 | 10.9 |
| 7.2 | 5.7 | (2R)-3-Hydroxyisovaleroylcarnitine | 21 | 0.1 | 3.0 |
| 7.1 | 5.0 | 3′-Sialyllactose | 21 | 0.3 | 5.7 |
| 6.6 | 5.7 | Galactonic acid | 16 | 0.5 | 0.8 |
| 6.4 | 5.2 | 1,4-Cyclohexanedicarboxylic acid | 15 | 0.3 | 2.4 |
| 6.3 | 4.2 | Gentisic acid | 64 | 0.4 | 2.3 |
| 6.1 | 2.4 | o-Hydroxyhippuric acid | 72 | 1.8 | 5.7 |
| 6.1 | 4.5 | Inosine | 18 | 0.4 | 1.0 |
| 6.0 | 1.5 | 7-Methyluric acid | 34 | 0.9 | 5.8 |
| 5.5 | 4.4 | Ribose-5-phosphate | 7 | 0.2 | 1.9 |
| 5.1 | 3.3 | 3-Methylhistidine | 17 | 0.7 | 1.0 |
| 5.0 | 2.9 | Phenylalanine | 31 | 0.5 | 0.0 |
| 4.4 | 3.0 | 4-Acetamidobutyric acid | 18 | 0.4 | 6.1 |
| 4.4 | 3.3 | N-α-methylhistamine | 26 | 0.2 | 13.2 |
| 4.3 | 2.7 | Betonicine | 14 | 0.5 | 1.0 |
| 4.3 | 1.4 | Nialamide | 47 | 0.3 | 0.2 |
| 4.3 | 3.0 | N-Methylleucine | 40 | 2.7 | 0.2 |
Candidate solutes are ordered by the kidney clearance association with furosemide clearance. iGFR, iohexol GFR; CoV, coefficient of variation; CLr-to-CrCl ratio, solute clearance-to-creatinine clearance ratio.